Our Mission

Numedicus Limited was established in 2008 to provide collaborative services to companies seeking expert advice in
the area novel uses for existing drugs, or ‘drug repurposing’.

Our Services

post
post

Types of collaborator

Numedicus uses therapeutic switching to identify secondary uses for existing drugs in practically all areas.

Read More
post

Types of switch

Therapeutic Switch, or drug repurposing projects, come in various different flavours

Read More
post

Methods and output

There are various different methods of identifying drug repurposing projects

Read More
post

Track Record

Numedicus has identified a number of clinical-stage drug repurposing projects, supported by method-of-use patents

Read More

About

post
post

David Cavalla has 31 years experience in various senior scientific and commercial roles within the pharmaceutical industry. He is currently involved with a number of biotech companies at Board level. Previously he was founder and CEO of Arachnova Ltd, a company focused on therapeutic switching; previous affiliations included Glaxo Group Research Ltd and Napp Research […]

Read More

Therapeutic Switching

post

Numedicus’ approach to new products is based on therapeutic switches, namely new uses for known drugs, and alternatively called ‘drug reprofiling’, ‘drug repositioning’ or ‘drug repurposing’.

Therapeutic switching is an area of huge potential, much still untapped, for identifying novel, patent protected medicines. Some examples are shown below.

Read More

Anti-hypertensive for cachexia

…coming soon

Read More

Anti-depressant for Rett syndrome

…coming soon

Read More

Anti-depressant for Respiratory depression

…coming soon

Read More

Anti-cancer for Acute Respiratory Distress Syndrome

…coming soon

Read More

The Empowerment of the Rare Disease Patient

The stakeholders in healthcare in the developed world are conventionally divided into three ‘P’ words: patients, payers and pharmaceutical companies. In addition, there are a couple of other more minor players, namely physicians and pharmacists. Recent developments have, however, dramatically increased the importance and changed the role of one of these participants, the patient community.

Read More

Value and cost-based pricing

David Grainger wrote recently on his DrugBaron blog about the pricing of pharmaceuticals. It is an intelligent piece, yet if I may I would like to improve upon it.

Read More

First-in-class new drug for cachexia

Numedicus is please to note the report from PsiOxus, on the outcome of a Phase II trial of MT-102, or s-pindolol, in cancer cachexia. David Cavalla is inventor of this technology (see EP2094254B1).

Read More

We need better evidence as a basis for off-label prescriptions

The practice of off-label prescription poses a significant issue for the advocates of evidence-based medicine, given that this area is particularly poorly served by data.

Read More

New book!

Off-Label Prescribing: Justifying Unapproved Medicine

Today’s medicines are regulated for their efficacy and safety and, once approved, they can be marketed for certain uses as justified by the data. Regulatory bodies in developed countries are constituted by legal statute and operate as parts of government, ostensibly in the interests of the people as patients.

But once approved, medicines can be used for any purpose the prescriber thinks fit and appropriate for the patient. One in five prescriptions is therefore written outside regulatory purview.

Off–label Prescribing looks into the corners of our medicated lives, where drug regulation runs up against medical practice, and concerns the use of a drug that has been approved for a different indication or on a different set of patients from the ones it is approved for, or at a different dose. Usually the patient is unaware of what is going on, having not been informed by their doctor of this aspect of his or her prescribing choice.

Reviews

1 Star2 Stars3 Stars4 Stars5 Stars
Loading...

5 months ago

A fascinating read lot more balanced and intellectually satisfying than the much higher profile Bad Pharma essential reading’, Medicines Information Director, NHS

1 Star2 Stars3 Stars4 Stars5 Stars
Loading...

5 months ago

‘Impressive fact-finding!’ department Head, AstraZeneca